Dr. Luis Diaz, Co-founder and CEO of DeepMind, discusses groundbreaking advances in immunotherapy for MMR-deficient rectal cancer, highlighting a 100% tumor regression rate without chemotherapy or surgery. He delves into the marriage between cancer genomics and immunotherapy, explores the implications of FDA approvals for checkpoint inhibitors, and unveils the game-changing potential of liquid biopsies for non-invasive cancer detection. Diaz also shares insights on improving early detection using machine learning, with transformative applications beyond oncology.
